Liquidia Corporation (LQDA)
| Market Cap | 7.01B +300.8% |
| Revenue (ttm) | 450.91M +2,233.6% |
| Net Income | 138.61M |
| EPS | 1.47 |
| Shares Out | 88.93M |
| PE Ratio | 53.43 |
| Forward PE | 17.42 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 3,990,741 |
| Open | 83.64 |
| Previous Close | 88.05 |
| Day's Range | 78.34 - 86.91 |
| 52-Week Range | 21.15 - 93.61 |
| Beta | 0.57 |
| Analysts | Buy |
| Price Target | 97.25 (+23.43%) |
| Earnings Date | Aug 12, 2026 |
About LQDA
Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for rare cardiopulmonary diseases in the United States. The company’s lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). It also provides Remodulin, a treprostinil injection administered through continuous intravenous and subcutaneous infusion; and develops L6... [Read more]
Financial Performance
In 2025, Liquidia's revenue was $158.32 million, an increase of 1031.18% compared to the previous year's $14.00 million. Losses were -$68.92 million, -46.28% less than in 2024.
Financial StatementsAnalyst Summary
According to 8 analysts, the average rating for LQDA stock is "Buy." The 12-month stock price target is $97.25, which is an increase of 23.43% from the latest price.
News
Liquidia Earnings Call Transcript: Q2 2026
YUTREPIA's rapid adoption drove 31% QoQ sales growth and nearly 30% market share in the inhaled prostacyclin segment, with strong profitability and cash flow supporting expanded R&D and commercial investments. The company remains confident in surpassing $1 billion in net revenue by 2027.
Liquidia Earnings release: Q2 2026
Liquidia released its Q2 2026 earnings on August 12, 2026, summarizing the period's financial results.
Liquidia Quarterly report: Q2 2026
Liquidia has published its Q2 2026 quarterly earnings report on August 12, 2026.
Liquidia Slides: Q2 2026
Liquidia has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on August 12, 2026.
Liquidia Corporation Reports Second Quarter 2026 Financial Results
YUTREPIA® (treprostinil) inhalation powder net product sales of approximately $170.4 million in the second quarter of 2026, up 31% from the first quarter of 2026 Approximately 5,900 unique patient pre...
Liquidia Corporation to Report Second Quarter 2026 Financial Results on August 12, 2026
MORRISVILLE, N.C., July 29, 2026 (GLOBE NEWSWIRE) -- Liquidia Corporation (Nasdaq: LQDA), a biopharmaceutical company driven by science and compassion to revolutionize care for patients with challengi...
Liquidia price target raised to $130 from $75 at H.C. Wainwright
H.C. Wainwright raised the firm’s price target on Liquidia (LQDA) to $130 from $75 and keeps a Buy rating on the shares, calling an order issued by Judge Andrews related…
Liquidia downgraded to Neutral from Buy at BofA
BofA downgraded Liquidia (LQDA) to Neutral from Buy with a price target of $79, up from $64. Yutrepia’s launch has exceeded the firm’s expectations, says the analyst, who raised the…
Liquidia price target raised to $109 from $59 at BTIG
BTIG raised the firm’s price target on Liquidia (LQDA) to $109 from $59 and keeps a Buy rating on the shares. The firm is updating its model while noting that…
Liquidia Transcript: AGM 2026
The meeting confirmed a quorum, introduced directors and officers, and approved all proposals, including director elections, auditor ratification, and executive compensation. No shareholder questions were raised, and forward-looking risks were referenced.
Liquidia Announces Poster Presentations at the PHA 2026 International PH Conference and Scientific Sessions
MORRISVILLE, N.C., June 11, 2026 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA), a biopharmaceutical company driven by science and compassion to revolutionize care for patients with challengi...
Liquidia announces inclusion in S&P SmallCap 600 Index
Liquidia (LQDA) announced that it will be added to the S&P SmallCap 600 Index, effective prior to the opening of trading on June 22.
Liquidia Corporation Announces Inclusion in the S&P SmallCap 600® Index
MORRISVILLE, N.C., June 08, 2026 (GLOBE NEWSWIRE) -- Liquidia Corporation (Nasdaq: LQDA), a biopharmaceutical company driven by science and compassion to revolutionize care for patients with challengi...
Liquidia price target raised to $75 from $67 at H.C. Wainwright
H.C. Wainwright raised the firm’s price target on Liquidia (LQDA) to $75 from $67 and keeps a Buy rating on the shares. The firm cites positive sentiment from the recent…
Raymond James sees positive readthrough for Liquidia from Hikma v. Amarin
Raymond James reiterated a Strong Buy rating and $68 price target on Liquidia (LQDA), with the analyst saying the firm is flagging Liquidia strength due to what it perceives to…
Liquidia Transcript: Jefferies Global Healthcare Conference 2026
YUTREPIA achieved rapid market penetration and strong revenue growth, with expansion into new indications and a robust clinical pipeline. The company is scaling its sales force, investing in manufacturing, and maintaining financial discipline while preparing for future market and legal developments.
Liquidia Corporation to Present at 2026 Jefferies Global Healthcare Conference
MORRISVILLE, N.C., May 27, 2026 (GLOBE NEWSWIRE) -- Liquidia Corporation (Nasdaq: LQDA) today announced that Dr. Roger Jeffs, Chief Executive Officer, and Michael Kaseta, Chief Operating Officer and C...
Liquidia Transcript: H.C. Wainwright 4th Annual BioConnect Investor Conference
YUTREPIA's launch has driven rapid revenue growth and profitability, with expansion into PAH and PH-ILD markets supported by robust clinical data and ongoing studies. The pipeline, including L606, targets further innovation, while strong physician relationships and reinvestment in R&D underpin future growth.
Liquidia Transcript: Bank of America Global Healthcare Conference 2026
YUTREPIA's launch has exceeded expectations, achieving rapid revenue growth, expanding market share, and maintaining strong financial discipline. The company is investing in clinical studies, sales force expansion, and manufacturing to capture a $3–5 billion market opportunity, with a $1 billion revenue target for 2027.
Liquidia price target raised to $67 from $55 at H.C. Wainwright
H.C. Wainwright analyst Andrew Fein raised the firm’s price target on Liquidia (LQDA) to $67 from $55 and keeps a Buy rating on the shares. Liquidia delivered a strong quarter…
Liquidia price target raised to $62 from $51 at Wells Fargo
Wells Fargo raised the firm’s price target on Liquidia (LQDA) to $62 from $51 and keeps an Overweight rating on the shares. The firm says Yutrepia appears to be disrupting…
Liquidia price target raised to $60 from $57 at Jefferies
Jefferies analyst Amy Li raised the firm’s price target on Liquidia (LQDA) to $60 from $57 and keeps a Buy rating on the shares following “strong” Q1 results. The firm…
Liquidia Earnings Call Transcript: Q1 2026
YUTREPIA drove 44% sequential sales growth and tripled EBITDA in Q1 2026, achieving over $500M annualized run rate. Market share in inhaled prostacyclins neared 23%, with robust expansion in both PAH and PH-ILD segments. Management maintains confidence in reaching $1B revenue by 2027.
Liquidia Earnings release: Q1 2026
Liquidia released its Q1 2026 earnings on May 11, 2026, summarizing the period's financial results.